The patent litigation group at Gibson, Dunn & Crutcher LLP stands out for its strong trial performance across administrative forums and federal courts, including the US Supreme Court. The team is primarily based in New York, and its client list includes industry leaders in tech, life sciences, software and electronics. Its recent high-profile work includes overturning an injunction that had barred its pharma client from launching new treatment due to a pending patent dispute. A global co-chair of the practice group, Josh Krevitt, remains actively involved in litigation, frequently advising companies on trial strategy. Kate Dominguez, co-head of the IP group, serves as lead counsel specialising in the tech sector. Another key leader within the team is Jane Love, a first-chair litigator recognised for her work in the life sciences, she is frequently sought out as a strategic trial advisor. Brian Rosenthal is another prominent litigator focusing on tech patents.
Legal 500 Editorial commentary
Phone
+1 212.351.2339
Email
Profile

Profile

Work Department
Intellectual Property
Position

Brian Rosenthal is a partner in the New York office of Gibson, Dunn & Crutcher. He is a member of the Intellectual Property practice. Brian is a trial lawyer with a particular emphasis on patent litigation. His patent litigation practice has spanned a wide range of technologies, with a concentration on computer software, electronics and medical devices.

Content supplied by Gibson, Dunn & Crutcher LLP

Key clients

  • Cisco
  • Verizon
  • T-Mobile
  • Dell
  • SharkNinja
  • Western Digital
  • Nvidia
  • Indeed.com
  • Uber Technologies
  • IBM
  • Plaid Technologies
  • Uniswap

Work highlights

Dismantled more than half a billion dollars in asserted claims, prevailing against both patent assertion entities and competitors in some of the most challenging venues in the country.
Erased over $1.3 billion in patent verdicts for Verizon and Western Digital, securing unprecedented reversals through groundbreaking trial advocacy, IPR victories, and post-trial strategy in two of the year’s highest-stakes cases.